Hematopoietic cell proliferation and differentiation

Current Opinion in Hematology

Volumn 3, Issue 4, 1996, Pages 321-328

  Spyridonidis, Alexandros ^a   Mertelsmann, Roland ^a   Henschler, Reinhard ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR;

ANIMAL CELL; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL TRANSPLANTATION; COLONY FORMATION; GENETIC MARKER; HEMATOPOIESIS; HEMATOPOIETIC CELL; IMMOBILIZED CELL; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; REVIEW; STEM CELL;

EID: 0030035785     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-199603040-00012     Document Type: Review

References (73)

1. Bennet CL, George SL, Vose JM, Nemunaitis JJ, Armitage JL, Armitage JO, Gorin NC, Gulati SC: Granulocyte-macrophage colony-stimulating factor as adjunct therapy in relapsed lymphoid malignancy: implications for economic analyses of phase III clinical trials. Stem Cells 1995, 13:414-420.
2. Schmitz N, Dreger P, Zander AR, Ehninger G, Wandt H, Fauser AA, Kolb HJ, Zumsprekel A, Martin A, Hecht T: Results of a randomised, controlled, multicentre study of recombinant human granulocyte colony stimulating factor (filgrastim) in patients with Hodgkin's disease and non-Hodgkin's lymphoma undergoing autologous bone marrow transplantation. Bone Marrow Transplant 1995, 15:261-266.
3. Madero L, Muonz A, Diaz de Heredia A, Martinez A, Badell I, Esquembre C, Ramirez M, Otheo E, Olive A, Sastre A, et al.: G-CSF after autologous bone marrow transplantation for malignant diseases in children. Spanish Working Party for Bone Marrow Transplantation in children. Bone Marrow Transplant 1995, 15:349-351.
4. Torres-Gomez A, Jimenez MA, Alvarez MA, Rodriguez A, Martin C, Garcia MJ, Flores R, Sanchez J, de la Torre MJ, Herrera C, et al.: Optimal timing of granulocyte colony stimulating factor (G-CSF) administration after bone marrow transplantation. A prospective randomized study. Ann Hematol 1995, 71:65-70.
5. Beyer J, Schwella N, Zingsem J, Strohscheer I, Schwaner I, Oettle H, Serke S, Huhn D, Stieger W: Hematopoietic rescue after high dose chemotherapy using autologous peripheral blood progenitor cells or bone marrow: a randomized comparison. J Clin Oncol 1995, 13:1328-1335. The authors show the superiority of PBPC rescue after high-dose chemotherapy over bone marrow in hematologic reconstitution but not in overall survival rate.
6. Klumpp TR, Mangan KF, Goldberg SL, Pearlmon ES, Macdonald JS: Granulocyte colony stimulating factor accelerates neutrophil engraftment following peripheral blood stem-cell transplantation: a prospective, randomized trial. J Clin Oncol 1995, 13:1323-1327.
7. Dunbar CE, Cottler-Fox M, O'Shaugnessy JA, Doren S, Carter C, •• Berenson R, Brown S, Moen RC, Greenblatt J, Stewart FM, et al.: Retrovirally marked CD34: enriched peripheral blood and bone marrow cells contribute to long-term engraftment after autologous transplantation. Blood 1995, 85:3048-3057. Important work showing that mobilized peripheral blood CD34-enriched cells contribute to long-term myeloid and lymphoid engraftment after autologous transplantation.
8. Negrin RS, Kusnierz-Glaz CR, Still BJ, Schriber JR, Chao NJ, Long GD, Hoyle C, Hu WW, Homing SJ, Brown BW, et al.: Transplantation of enriched and purged peripheral blood progenitor cells from a single apheresis product in patients with non-Hodgkin's lymphoma. Blood 1995, 85:3334-3341.
9. van der Wall E, Nooijen WJ, Bears JW, Holtkamp MJ, Schorangel JH, Richel DJ, Rutgers EJ, Slaper-Cortenbach IC, van der Schoot CE, Rodenhuis S: High-dose carboplatin, thiotepa and cyclophosphamide (CTC) with peripheral blood stem cell support in the adjuvant therapy of high-risk breast cancer: a practical approach. Br J Cancer 1995, 71:857-862.
10. Nakagawa H, Fujii H, Ariyama Y, Sonoda Y: Peripheral blood stem cell collection with high dose etoposide. Rinsho Ketsueki 1995, 36:185-192.
11. Demirer T, Rowley S, Buckner CD, Appelbaum FR, Lilleby K, Storb R, Schiffman K, Bensinger WI: Perlpheral-blood-stem-cell-collections after paclitaxel, cyclophosphamide, and recombinant human granulocyte colony stimulating factor in patients with breast and ovarian cancer. J Clin Oncol 1995, 13:1714-1719.
12. Schwarzberg L, Birch R, Blanco R, Wittlin F, Muscato J, Tauer K, Hazelton B, West W: Rapid and sustained hematopoletic reconstitution by peripheral blood stem cell infusion alone following high dose chemotherapy. Bone Marrow Transplant 1995, 11:369-374.
13. Fennelly D, Bengala C, Schneider J, Reich I, Norton L, Spriggs D, Moore MAS, Crown J: Peripheral blood progenitor cell mobilization using Taxol in combination with cyclophosphamide and G-CSF; quantitation and correlation of CD34+ cell count, colony-forming-unit-granulocyte-macrophage (CFU-GM) and mononuclear cell count [abstract]. Blood 1994, 84(suppl 1):409a.
14. Schwarztberg LS, Birch I, Hazelton B, Tauer KW, Lee P Jr, Altemose R, George C, Blanco R, Wittlin F, Cohen J, et al.: Peripheral blood stem cell mobilization by chemotherapy with and without recombinant human granulocyte colony stimulating factor. J Hematother 1992, 1:317-327.
15. Demuynck H, Delforge M, Verhoef G, Zachee P, Vandenderghe P, Boogaerts M: Comparative study of peripheral blood progenitor cell collection in patients with multiple myeloma after single dose cyclophosphamide combined with rhGM-CSF or rhG-CSF. Br J Haematol 1995, 90:384-392.
16. Willerford DM, Preffer F, McAfee S, Scavone M, Spitzer TR: Mobilization of early and late hematopoletic precursors using GM-CSF, G-CSF or combined GM-CSF and G-CSF following chemotherapy [abstract]. Blood 1994, 84(suppl 1):350a.
17. Brugger W, Bross K, Frisch J, Dem P, Weber B, Mertelsmann R, Kanz L: Mobilization of peripheral blood progenitor cells by sequential administration of interleukin-3 and granulocyte-macrophage colony stimulating factor following polychemotherapy with etoposide, ifosfamide, and cisplatin. Blood 1992, 79:1193-1200
18. Hogge DE, Eaves CJ, Sutherland HJ, Lansdorp PM, Phillips GL: Administration of IL-3 with GM-CSF after high-dose cyclophosphamide mobilizes blood progenitors which enhance platelet recovery following autologous transplantation [abstract]. Blood 1994, 84(suppl 1):412a.
19. D'Hondt V, Guillaume T, Humblet Y, Doyen C, Chatelain B, Feyens AM, Staquet P, Osselaer JC, Mull B, Symann M: Tolerance of sequential or simultaneous administration of IL-3 and G-CSF in improving peripheral blood stem cells harvesting following multi-agent chemotherapy: a pilot study. Bone Marrow Transplant 1994, 13:261-264
20. Kessinger A, Bishop MR, Jackson JD, O'Kane-Murphy B, Vose JM, • Bierman PJ, Reed EC, Warkentin PI, Armitage JO, Sharp JG: Erythropoietin for mobilization of circulating progenitor cells in patients with previously treated relapsed malignancies. Exp Hematol 1995, 23:609-612. This study demonstrates the mobilization properties of etythropoietin.
21. Laterveer L, Lindley IJD, Hamilton MS, Willemze R, Fibbe WE: Interleukin-8 induces rapid mobilization of hematopoletic stem cells with radio-protective capacity and long-term myelolymphoid repopulating ability. Blood 1995, 85:2269-2275.
22. Glaspy J, McNiece I, LeMaistre F, Menchaca D, Briddell R, Lill M, Jones R, Tami J, Morstyn G, Brown S, Shpall EJ: Effects of stem cell factor (rhSCF) and filgrastim (rhG-CSF) on mobilization of peripheral blood progenitor cells (PBPC) and on hematologic recovery posttransplant: early results from a phase I/II study [abstract]. Proc Am Soc Clin Oncol 1994, 13:76a.
23. Bishop MR, Vose JM, Bierman PJ, Armitage JO, Garrison L, Schmit-Pokorny K, Kessinger A: Phase I trial of PIXY 321 for peripheral stem cell mobilization in patients with lymphoid malignancies. Exp Hamatol 1994, 22:3693.
24. Haas R, Mohle R, Fruhauf S, Goldschmidt H, Witt B, Flentje M, Wannenmacher M, Hunstein W: Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood 1994, 83:3787-3794.
25. Glaspy J, Chap L, Menchaca D, Hill J, Norton L, Mc Niece I, Lill M: Effect of prior chemotherapy on peripheral blood progenitor cell (PBPC) harvests in patients with breast cancer [abstract]. Proc Am Soc Clin Oncol 1995, 14:943a.
26. Locatelli F, Pession A, Zecca M, Bonetti F, Prete L, Carra AM, Prete A, Montagna D, Comoli P, Taibi RM, Paolucci G: Use of recombinant human granulocyte colony stimulating factor in children given allogeneic bone marrow transplantation for acute or chronic leukemia. Bone Marrow Transplant 1996, 17:31-37.
27. Weisdorf DJ, Verfaillie CM, Davies SM, Filipovich AH, Wagner JE Jr, Miller JS, Burroughs J, Ramsay NK, Kersey JH, McGlave PB, et al.: Hematopoletic growth factors for graft failure after bone marrow transplantation: a randomized trial of granulocyte-macrophage colony stimulating factor (GM-CSF) versus sequential GM-CSF plus granulocyte-CSF. Blood 1995, 85:3452-3456.
28. Biggs JC, Atkinson KA, Booker V, Concannon A, Dart GW, Dodds A, Downs K, Szer J, Turner J, Worthington R: Prospective randomised double-blind trial of the in vivo use of recombinant human erythropoi-etin in bone marrow transplantation from HLA-identical sibling donors. The Australian Bone Marrow Transplant Group. Bone Marrow Transplant 1995, 15:129-134.
29. Bensinger WI, Weaver CH, Appelbaum FR, Rowley S, Demirer T, Sanders • J, Storb R, Buckner CD: Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor. Blood 1995, 85:1655-1658. Pioneering work using allogeneic PBPCs.
30. Körbling M, Przepiorka D, Huh YO, et al.: Allogeneic blood stem cell • transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts. Blood 1995, 85:1659-1665. Pioneering work using allogeneic PBPCs.
31. Russell J, Bowen T, Brown C, Luider J, Weaver M, Coppes M, Jorgenson K, Klassen J: Single centre experience of allogeneic blood cell transplants: accelerated engraftment without increased acute GVHD compared with BMT [abstract]. Bone Marrow Transplant 1995, 15(suppl 2):S5a.
32. Bacigalupo A, Majolino I, Van Lint MT, Vasta S, Valbonesi M, Lercri G, Carlier P, Occhini D, Gualandi F, Lamparelelli T, et al.: Transplantation of rh-G-CSF mobilized allogeneic peripheral blood cells from HLA identical sibling donors [abstract]. Bone Marrow Transplant 1995, 15(suppl 2):S5a.
33. Schmitz N, Dreger P, Suttorp M, et al.: Primary transplantation of allo• geneic peripheral blood progenitor calls mobilized by Fllgrastim (G-CSF). Blood 1995, 85:1666-1672. Pioneering work using allogeneic PBPCs.
34. Azevedo WM, Aranha FJ, Gouvea JV, Vigorito AC, Marques JF Jr, Eid KA, Azevedo AM, Souza CA: Allogeneic transplantation with blood stem cells mobilized by rhG-CSF for hematological malignancies. Bone Marrow Transplantation 1995, 16:647-653
35. Rozman C, Urbano-Ispizua A, Sierra J, Merino A, Rovira M, Battle M, Salgado C, Marin P, Carreras E, Montserrat E: Allogeneic peripheral blood stem cell (PBPC) transplantation. Report of four cases [abstract]. Bone Marrow Transplant 1995, 15(suppl 2):S27a.
36. Dreger P, Haferlach T, Eckstein V, Jacobs S, Suttorp M, Loffler H, Mullerruchholtz W, Schmitz N: G-CSF mobilized peripheral blood progenitor cells for allogeneic transplantation: safety, kinetics of mobilization, and composition of the graft Br J Haematol 1994, 87:609-613.
37. Takeshita A, Ohno R, Hirashima K, Toyama K, Okuma M, Saito H, Ikeda Y, Tomonaga M, Asano S: A randomized double blind-blind controlled study of recombinant human granulocyte colony stimulating factor in patients with neutropenia induced by consolidation chemotherapy for acute myeloid leukemia. (rG-CSF clinical study group). Rinsho Ketsueki 1995, 36:606-614.
38. Nakajima H, Ikeda Y, Hirashima K, Toyama K, Okuma M, Saito H, Ohno R, Tomonaga M, Asano S: A randomized controlled study of rG-CSF in patients with neutropenia after induction therapy for acute myelogenous leukemia (rG-CSF Clinical Study Group). Rinsho Ketsueki 1995, 36:597-605.
39. Dombret H, Chastang C, Fenaux P, Reiffers J, Bordessoule D, Bouabdallah R, Mandelli F, Ferrant A, Auzanneau G, Tilly H, et al.: A controlled study of recombinant human granulocyte colony stimulating factor in elderly patients after treatment for acute myelogenous leukemia. AML Cooperative Study Group. N Engl J Med 1995, 332:1678-1683.
40. Ottmann OG, Hoelzer D, Gracien E, Ganser A, Kelly K, Reutzel R, Lipp T, Busch FW, Schwonzen M, Heil G, et al.: Concomitant granulocyte colony stimulating factor and induction chemotherapy in adult acute lymphobiastic leukemia: a randomized phase III trial. Blood 1995, 86:444-450.
41. Dibenedetto SP, Ragusa R, Ippolito AM, Lo Nigro L, Di Cataldo A, D'Amico S, Miraglia V: Assessment of the value of treatment with granulocyte colony stimulating factor in children with acute lymphoblastic leukemia: a randomized clinical trial. Eur J Haematol 1995, 55:93-96.
42. Dotti G, Stella CC, Mangoni L, Cottafavi L, Caramatti C, Almici C, Rizzoli V: Granulocyte colony stimulating factor (G-CSF) prevents dose limiting neutropenia in lymphoma patients receiving standard dose chemotherapy. Haematologica 1995, 80:142-145.
43. Silvestri F, Velisig M, Fanin R, Virgolini R, Zaja F, Barillary G, Baccarani M: Granulocyte colony stimulating factor (G-CSF) allows the delivery of effective doses of CHOP and CVP regimens in non-Hodgkin lymphomas. Leuk Lymphoma 1995, 16:465-470.
44. Mangiagalli M, Miccolis I, Maffe P, Pogliani EM, Corneo G: Role of granulocyte colony stimulating factor in relapsed/resistant intermediate and high-grade non-Hodgkin's lymphoma patients treated with the ESHAP regimen. Tumori 1995, 81:91-95.
45. Riikonen P, Rahiala J, Salonvaara M, Perkkio M: Prophylactic administration of granulocyte colony stimulating factor (filgrastim) after conventional chemotherapy in children with cancer. Stem Cells 1995, 13:289-294.
46. Mayordomo JI, Rivera F, Diaz-Puente MT, Lianes P, Colomer R, Lopez-Brea M, Lopez E, Paz-Ares L, Hitt R, Garcia Ribas I, et al.: Improving treatment of chemotherapy-induced neutropenic fever by administration of colony stimulating factors. J Natl Cancer Inst 1995, 87:803-808.
47. Urabe A, Mizoguchi H, Asano S, Tsuruoka N, Kobayashi M, Hirashima K, Yoshida M, Miura Y, Hirai H, Kamakura M, et al.: Efficacy of combination chemotherapy with miconazole and G-CSF in deep mycosis accompanying hematological diseases. Kansenshogaku Zasshi 1995, 69:701-710.
48. Liang DC, Chen SH, Lean SF: Role of granulocyte colony stimulating factor as adjunct therapy for septicemia in children with acute leukemia. Am J Hematol 1995, 48:76-81.
49. Woll PJ, Hodgetts J, Lomax L, Bildet F, Cour Chabernaud V, Thatcher N: Can cytotoxic dose intensity be increased by using granulocyte colony stimulating factor? A randomized controlled trial of lenogastrim in small-cell lung cancer. J Clin Oncol 1995, 13:652-659.
50. Lilenbaum RC, Ratain MJ, Miller AA, Hargis JB, Hollis DR, Rosner GL, O'Brien SM, Brewster L, Green MR, Schilsky RL: Phase I study of paclltaxel and topotecan in patients with advanced tumors: a Cancer and Leukemia Group B study. J Clin Oncol 1995, 13:2230-2237.
51. Langer CJ, Leighton JC, Comis RL, O'Dwyer PJ, McAleer CA, Bonjo CA, Engstrom PF, Litwin S, Johnson S, Ozols RF: Paclltaxel by 24- or 1-hour infusion in combination with carboplatin in advanced non-small cell lung cancer the Fox Chase Cancer Center experience. Semin Oncol 1995, 22(4 suppl 9):18-29.
52. Langer CJ, Leighton J, McAleer C, Comis R, O'Dwyer P, Ozols R: Paclitaxel and carboplatin in the treatment of advanced non-small cell lung cancer. Semin Oncol 1995, 22(3 suppl 6):64-69.
53. Chevallier B, Chollet P, Merrouche Y, Roche H, Fumoleau P, Kerbrat P, Genot JY, Fargeot P, Olivier JP, Fizames C, et al.: Lenogastrim prevents morbidity from intensive induction chemotherapy in the treatment of Inflammatory breast cancer. J Clin Oncol 1995, 13:1564-1571.
54. Rowe JM, Andersen JW, Mazza JJ, Bennett JM, Paietta E, Hayes FA, Oette D, Cassileth PA, Stadtmauer EA, Wiemik PH: A randomized placebo-controlled phase III study of granulocyte-macrophage colony stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490). Blood 1995, 86:457-462.
55. Heil G, Chadid L, Hoelzer D, Seipelt G, Mitrou P, Huber C, Kolbe K, Mertelsmann R, Lindemann A, Frisch J, et al.: GM-CSF in a double-blind randomized placebo controlled trial in therapy of adult patients with de novo acute myelold leukemia (AML). Leukemia 1995, 9:3-9.
56. Hansen PB, Johnsen HE, Lund JO, Hansen MS, Hansen NE: Unexpected hepatotoxicity after priming and treatment with molgramostim (rhGM-CSF) in acute myeloid leukemia during induction chemotherapy. Am J Hematol 1995, 48:48-51.
57. Bajorin DF, Nichols CR1 Schmoll HJ, Kantoff PW, Bokmeyer C, Demetri GD, Einhorn LH, Bosl GJ: Recombinant human granulocyte-macrophage colony stimulating factor as an adjunct to conventional-dose ifosfamide-based chemotherapy for patients with advanced or relapsed germ cell tumors: a randomized trial. J Clin Oncol 1995, 13:79-86.
58. Bunn PA Jr, Crowley J, Kelly K, Hazuka MB, Beasley K, Upchurch C, Livingston R: Chemoradiotherapy with or without granulocyte-macrophage colony stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group. J Clin Oncol 1995, 13:1632-1641.
59. Troussard X, Macro M, Vie B, Batho A, Peny AM, Reman O, Tabah I, Leporrier M: Human recombinant granulocyte-macrophage colony stimulating factor (rhGM-CSF) improves double hemibody irradiation (DHBI) tolerance in patients with stage III multiple myeloma: a pilot study. Br J Haematol 1995, 89:191-195.
60. Garton JP, Grtz MA, Witzig TE, Greipp PR, Lust JA, Schroeder G, Kyle RA: Epoetin alfa for the treatment of the anemia of multiple myeloma. A prospective, randomized, placebo-controlled, double-blind trial. Arch intern Med 1995, 155:2069-2074.
61. Silvestris F, Romito A, Fanelli P, Vacca A, Dammaco F: Long-term therapy with recombinant human erythropoietin (rHu-Epo) in progressing multiple myeloma. Ann Hematol 1995, 70:313-318.
62. Lopez KD, Guinan EC: GM-CSF clinical trials: pediatric aplastic anemia and Fanconi's anemia. Pediatr Nurs 1995, 21:345-349.
63. Schrezenmeier H, Marsh JC, Stromeyer P, Muller H, Heimpel H, Gordon-Smith EC, Raghavachar A: A phase I/II trial of recombinant human interleukin-6 in patients with aplastic anaemia. Br J Haematol 1995, 90:283-292.
64. Rose EH, Abels RI, Nelson RA, McCullough DM, Lessin L: The use of rHu-Epo in the treatment of anaemia related to myelodysplasia (MDS). Br J Haematol 1995, 89:831-837.
65. Runde V, Aul C, Ebert A, Grabenhorst U, Schneider W: Sequential administration of recombinant human granulocyte-macrophage colony-stimulating factor and human erythropoletin for treatment of myelodysplastic syndromes. Eur J Haematol 1995, 54:39-45.
66. Gordon MS, Nemunaitis J, Huffman R, Raquette RL, Rosenfeld C, Manfreda S, Issacs R, Nimer CD: A phase I trial of recombinant human interleukin-6 in patients with myetodysplastic syndromes. Blood 1995, 85:3066-3076.
67. Pangalis GA, Poziopoulos C, Angelopoulou MK, Siakantaris MP, Panayiotidis P: Effective treatment of disease related anaemia in B-chronic lymphocytic leukaemia patients with recombinant human erythropoietin. Br J Haematol 1995, 89:627-629.
68. de Cambos E, Radford J, Steward W, Milroy R, Dougal M, Swindell R, Testa N, Thatcher N: Clinical and in vitro effects of recombinant human erythropoietin in patients receiving intensive chemotherapy for small-cell lung cancer. J Clin Oncol 1995, 13:1623-1631.
69. Beck MN, Beck D: Recombinant erythropoietin in acute chemotherapy induced anemia of children with cancer. Med Pediatr Oncol 1995, 25:17-21.
70. Huhn RD, Yurkow EJ, Kuhn JG, Clarke L, Gunn H, Resta D, Shah R, Myers LA, Seibold JR: Pharmacodynamlcs of dairy subcutaneous recombinant human interleukin-3 in normal volunteers. Clin Pharmacol Ther 1995, 57:32-41.
71. Speyer JL, Mandeli J, Hochster H, Runowicz C, Wadler S, Wallach R, Cohen C, Oette D, Sorich J, Demakos E, et al.: A phase I trial of cyclophosphamide and carboplatinum combined with interleukin-3 in women with advanced stage ovarian cancer. Gynecol Oncol 1995, 56:387-394.
72. Hovgaard DJ, Nissen NI: Effects of interleukin-3 following chemotherapy of non-Hodgkin's lymphoma. A prospective, controlled phase I/II study. Eur J Haematol 1995, 54:78-84.
73. Vadhan-Raj S, Broxmeyer HE, Andreeff M, Bandres JC, Buescher ES, •• Benjamin RS, Papadopoulos NE, Burgess A, Patel S, Plager C, et al.: In vivo biologic effects of PIXY321, a synthetic hybrid protein of recombinant human granulocyte-macrophage colony stimulating factor and interleukin-3 in cancer patients with normal hematopoiesis: a phase I study. Blood 1995, 86:2098-2105. Careful analysis of the influence of PIXY321 on a variety of important in vivo and in vitro parameters of hematopoietic cell proliferation and differentiation.